Glioma in 2014: Unravelling tumour heterogeneity - Implications for therapy

Nature Reviews Clinical Oncology

Volumn 12, Issue 2, 2015, Pages 69-70

  Reardon, David A ^a   Wen, Patrick Y ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TEMOZOLOMIDE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BLOOD BRAIN BARRIER; CANCER THERAPY; CELL HETEROGENEITY; CELL ISOLATION; CHEMORADIOTHERAPY; CHROMOSOME ABERRATION; DISEASE COURSE; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; HYPOXIA; IDH1 GENE; IMMUNE RESPONSE; KARNOFSKY PERFORMANCE STATUS; MISMATCH REPAIR; MOLECULARLY TARGETED THERAPY; OLIGODENDROGLIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RNA SEQUENCE; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH; GENETIC HETEROGENEITY; GENETICS; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84961331128     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.223     Document Type: Short Survey

References (10)

1. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396-1401 (2014).
2. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014).
3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
4. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
5. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
6. Taal, W. et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 15, 943-953 (2014).
7. Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709-722 (2014).
8. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708 (2014).
9. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
10. Phillips, H. S. et al. Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]) [abstract]. J. Clin. Oncol. 32 (Suppl.), a2001 (2014).